Entertainment One: Numis upgrades to add with a target price of 340p.
Kevin Havelock, a non-executive director of carbonated drinks maker FeverTree, purchased 9,000 ordinary shares in the AIM-listed firm on Friday.
AIM-listed posh mixers maker Fevertree Drinks said on Thursday that the first four months of this year have seen further progress after 2017 proved to be another year of strong growth, with "impressive" rates of sale growth and market share gains.
Fevertree Drinks shares are now one to 'avoid' said the Sunday Times' Inside the City column, having increased almost 2000% from its flotation four years ago at 134p. Co-founder Charles Rolls sold a 2.6% stake last week, which saw the share price drop 5% to 2,807p. The company therefore has £3.2bn market cap, but turned over £170.2m in 2017 and generated £56.4m in profit.
Posh mixers maker Fevertree Drinks slumped on Friday as co-founder and deputy chairman Charles Rolls sold 3m shares in the company, or a 2.6% stake.
Close Brothers Group plc: Berenberg downgrades to hold with a target price of 1,530p.
Fevertree Drinks, a supplier of premium drink mixers, reported a 64% jump in full-year pre-tax profit on Tuesday as revenue rose amid growth across the group.
Fever-Tree fizzed higher on Wednesday as the posh tonic maker said the outcome for the full-year will be "comfortably ahead" of market expectations on the back of "very strong" growth.
Fever-Tree: Jefferies initiates buy with a target price of 3000p.
Fevertree Drinks is in a "unique" position to capitalise on the 'premiumisation' or 'gin-naissance' trends in the drink industry, analysts believe, leading to rumours on Friday that the company may be a takeover target.
Carbonated mixers maker Fever-Tree has established an office in North America which will be headed up by Charles Gibb.
Fevertree Drinks said on Tuesday that results for the year to the end of December are set to be "materialy ahead" of current market expectations following a strong performance in the year to date.
South32: Deutsche Bank downgrades to Sell with a target price of 170p.
Analysts at RBC Capital Markets slashed their target price on shares of Fevertree ahead of the re-launch of Schweppes's more premium 1783 brand and in light of the recent acceleration in the rate of organic growth in the company's sales in the UK market to over 60% since the backhalf of 2016.
Standard Chartered: Deutsche Bank upgrades to Hold with a target price of 653p.
AstraZeneca: Morgan Stanley downgrades to Equal Weight with a target price of 4700p.
Fevertree Drinks chief executive and co-founder, Tim Warrillow, has sold £29m worth of shares in the company.
Shares in Fevertree Drinks fizzed higher on Tuesday after the supplier of carbonated mixers upgraded its full-year guidance and reported a surge in first-half pre-tax profit on the back of strong growth across all regions, channels and flavours.
Charles Rolls, a non-executive director and one of the founders of drink mixers maker Fever-Tree has pocketed £73m from the sale of 4.5m shares in the company, or a 3.9% stake.
Drink mixers maker Fever-Tree said on Monday that it expects results for the year ending 31 December to be "comfortably ahead" of current market expectations thanks to strong sales.